DK3532459T3 - Lsd1-hæmmere og medicinske anvendelser deraf - Google Patents

Lsd1-hæmmere og medicinske anvendelser deraf Download PDF

Info

Publication number
DK3532459T3
DK3532459T3 DK17797805.3T DK17797805T DK3532459T3 DK 3532459 T3 DK3532459 T3 DK 3532459T3 DK 17797805 T DK17797805 T DK 17797805T DK 3532459 T3 DK3532459 T3 DK 3532459T3
Authority
DK
Denmark
Prior art keywords
medical uses
lsd1 inhibitors
lsd1
inhibitors
medical
Prior art date
Application number
DK17797805.3T
Other languages
English (en)
Inventor
Francois Brucelle
Victor S Gehling
Avinash Khanna
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3532459T3 publication Critical patent/DK3532459T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
DK17797805.3T 2016-10-26 2017-10-26 Lsd1-hæmmere og medicinske anvendelser deraf DK3532459T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413166P 2016-10-26 2016-10-26
US201662413162P 2016-10-26 2016-10-26
PCT/US2017/058405 WO2018081343A1 (en) 2016-10-26 2017-10-26 Lsd1 inhibitors and medical uses thereof

Publications (1)

Publication Number Publication Date
DK3532459T3 true DK3532459T3 (da) 2023-10-30

Family

ID=60320993

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17797805.3T DK3532459T3 (da) 2016-10-26 2017-10-26 Lsd1-hæmmere og medicinske anvendelser deraf

Country Status (17)

Country Link
US (3) US10517849B2 (da)
EP (1) EP3532459B1 (da)
JP (1) JP7142633B2 (da)
CN (1) CN109863137B (da)
AU (1) AU2017348100B2 (da)
CA (1) CA3039793A1 (da)
DK (1) DK3532459T3 (da)
ES (1) ES2961499T3 (da)
FI (1) FI3532459T3 (da)
HR (1) HRP20231369T1 (da)
HU (1) HUE063848T2 (da)
LT (1) LT3532459T (da)
PT (1) PT3532459T (da)
RS (1) RS64889B1 (da)
SI (1) SI3532459T1 (da)
TW (1) TWI753037B (da)
WO (1) WO2018081343A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64889B1 (sr) 2016-10-26 2023-12-29 Constellation Pharmaceuticals Inc Inhibitori lsd1 i njihova medicinska upotreba
JP2020529995A (ja) 2017-08-03 2020-10-15 オリゾン ジェノミックス ソシエダッド アノニマ 行動の変化の治療方法
WO2020052649A1 (zh) * 2018-09-13 2020-03-19 南京明德新药研发有限公司 作为lsd1抑制剂的环丙胺类化合物及其应用
KR20210141933A (ko) 2019-03-20 2021-11-23 오리존 지노믹스 에스.에이. 경계성 인격 장애의 치료 방법
EP3941465A1 (en) 2019-03-20 2022-01-26 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
KR20230167102A (ko) 2021-04-08 2023-12-07 오리존 지노믹스 에스.에이. 골수성 암 치료를 위한 lsd1 억제제의 조합물
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639273A (en) 1983-05-06 1987-01-27 Morton Thiokol, Inc. Asphalt-adhesion improving additives prepared by formaldehyde condensation with polyamines
WO1987007637A2 (en) 1986-06-13 1987-12-17 The Lubrizol Corporation Phosphorus-containing lubricant and functional fluid compositions
DE69129166T2 (de) 1990-06-15 1998-07-30 Fuji Photo Film Co Ltd Zusammensetzung und Verfahren zur Verarbeitung eines farbphotographischen Silberhalogenidmaterials
WO1992017456A1 (en) 1991-03-26 1992-10-15 Fujisawa Pharmaceutical Co., Ltd. Amino acid derivative and salt thereof
US5344467A (en) 1991-05-13 1994-09-06 The Lubrizol Corporation Organometallic complex-antioxidant combinations, and concentrates and diesel fuels containing same
TW230781B (da) 1991-05-13 1994-09-21 Lubysu Co
FR2687932A1 (fr) 1992-02-27 1993-09-03 Oreal Dispersion huile-dans-l'eau susceptible de former des films composites.
DE4224414A1 (de) 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
EP0678786B1 (en) 1994-04-19 1998-06-17 Agfa-Gevaert N.V. A method for making a lithographic printing plate
DE19523288A1 (de) 1995-06-27 1997-01-02 Basf Ag Iminooxybenzylverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung
SE9600590D0 (sv) 1996-02-19 1996-02-19 Pharmacia Biotech Ab Sätt för kromatografisk separation av peptider och nukleinsyra samt ny högaffin jonbytesmatris
US6492380B1 (en) 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
ES2228549T3 (es) 1999-06-15 2005-04-16 Bristol-Myers Squibb Pharma Company Gamma-carbolinas condensadas con heterociclo sustituido.
ECSP003599A (es) 1999-08-06 2002-03-25 Smithkline Beecham Corp Procedimiento para preparar acidos a traves de alfa-coroepoxi-esteres
US7135437B2 (en) 2000-05-19 2006-11-14 Monsanto Technology Llc Stable liquid pesticide compositions
MY158895A (en) 2000-05-19 2016-11-30 Monsanto Technology Llc Potassium glyphosate formulations
WO2002000623A2 (en) 2000-06-26 2002-01-03 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US7008904B2 (en) 2000-09-13 2006-03-07 Monsanto Technology, Llc Herbicidal compositions containing glyphosate and bipyridilium
US6518444B1 (en) 2000-12-18 2003-02-11 Univation Technologies, Llc Preparation of polymerization catalysts
US20030096708A1 (en) 2001-03-02 2003-05-22 Monsanto Technology Llc Pesticide concentrates containing etheramine surfactants
EP1389040B1 (en) 2001-05-21 2010-05-19 Monsanto Technology LLP Pesticide concentrates containing etheramine surfactants
WO2003003008A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
JP2003064035A (ja) 2001-08-28 2003-03-05 Sony Corp 部分フッ化アルキル系化合物、該化合物からなる潤滑剤および該潤滑剤を用いた記録媒体
KR100577179B1 (ko) 2001-10-30 2006-05-10 엘지전자 주식회사 유기 전계 발광 소자
DE10302781B4 (de) 2002-02-23 2015-08-27 Merck Patent Gmbh Verfahren zur α,α-Difluoralkylierung von Stickstoffnucleophilen
WO2004014388A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2004014377A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
FR2843750B1 (fr) 2002-08-23 2004-10-22 Cerep Composes derives d'arylcarbamates, preparation et utilisations
MXPA05002368A (es) 2002-08-31 2005-05-23 Monsanto Technology Llc Composiciones de pesticidas que contienen acidos dicarboxilicos.
US7759336B2 (en) 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
JP4123361B2 (ja) 2002-12-11 2008-07-23 ライオン株式会社 漂白性組成物
WO2004078686A1 (en) 2003-03-07 2004-09-16 Kawaken Fine Chemicals Co., Ltd. Process for producing optically active alcohol in the presence of rhodium, a chiral ferrocenyldiphosphine and an optically active diamine
US7678281B2 (en) 2003-07-18 2010-03-16 Bj Services Company Method of reclaiming brine solutions using an organic chelant
US7172703B2 (en) 2003-07-18 2007-02-06 Bj Services Co Method of reclaiming a well completion brine solutions using an organic chelant
EP1679309A4 (en) 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
JP4789966B2 (ja) 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
CN1942433A (zh) 2004-04-27 2007-04-04 北卡罗来纳查佩尔山大学 通过液相色谱法分离不对称二亚胺
DE102005022593A1 (de) 2004-05-18 2006-02-16 Sasol Wax (South Africa) (Pty.) Ltd. Polymerisation von Olefinverbindungen
WO2005118543A1 (ja) 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
ATE523250T1 (de) 2004-06-18 2011-09-15 Sasol Tech Pty Ltd Oligomerisation in gegenwart sowohl eines tetramerisationskatalysators als auch eines weiteren oligomerisationskatalysators
PL1773768T3 (pl) 2004-07-30 2019-03-29 Exelixis, Inc. Pochodne pirolu jako środki farmaceutyczne
FR2874010B1 (fr) 2004-08-04 2006-09-29 Rhodia Chimie Sa Procede d'acylation de composes nucleophiles notamment anilines
GB0421285D0 (en) 2004-09-24 2004-10-27 Univ Nottingham Improvements in high content screening
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
US20090110720A1 (en) 2004-10-06 2009-04-30 Anders Nykjaer Use of compounds for the prevention of drug-induced cell toxicity
AU2006275694A1 (en) 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
CA2621949A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2624866A1 (en) 2005-10-13 2007-04-19 Wyeth Methods for preparing glutamic acid derivatives
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007116011A2 (de) 2006-04-10 2007-10-18 Basf Se Substituierte triazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
JP4771975B2 (ja) 2007-02-27 2011-09-14 三菱製紙株式会社 可逆性感熱記録材料
CN101622231B (zh) 2007-02-28 2013-12-04 艾德维纳斯医疗私人有限公司 作为葡糖激酶激活剂的2，2，2-三取代的乙酰胺衍生物、它们的制造方法和药学应用
US20100305056A1 (en) 2007-11-29 2010-12-02 Merck Frosst Canada Ltd. Cysteine protease inhibitors for the treatment of parasitic disease
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
CA2716514A1 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Hiv protease inhibitor and cytochrome p450 inhibitor combinations
DE102008017215B4 (de) 2008-04-04 2012-08-09 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden ethylenisch ungesättigter Carbonsäuren
US20100055169A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
WO2010007317A1 (fr) 2008-07-18 2010-01-21 Sanofi-Aventis NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
JP5649779B2 (ja) 2008-11-28 2015-01-07 住友化学株式会社 液晶性組成物及び光学フィルム
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
DK2433940T3 (da) 2009-04-28 2015-01-12 Chugai Pharmaceutical Co Ltd Spiroimidazolonderivat
EP2416652B1 (en) 2009-05-05 2018-11-07 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
WO2010148422A1 (en) 2009-06-25 2010-12-29 Walter And Eliza Hall Institute Of Medical Research Compounds and methods for treating parasitic infestations
BRPI1012681B1 (pt) 2009-06-26 2019-03-26 China Petroleum & Chemical Corporation Composição de diesel e método de aumentar a estabilidade de oxidação de biodiesel
ES2360783B1 (es) 2009-10-02 2012-07-04 Consejo Superior De Investigaciones Científicas (Csic) 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
JP2012077108A (ja) 2010-09-30 2012-04-19 Sumitomo Chemical Co Ltd ジハロビフェニル化合物及び該化合物の重合体
SG182932A1 (en) 2011-01-24 2012-08-30 Sumitomo Chemical Co Process for producing conjugated diene-based polymer, conjugated diene-based polymer, and conjugated diene-based polymer composition
CN103826661B (zh) 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
WO2012146338A1 (en) 2011-04-27 2012-11-01 Merck Patent Gmbh Method for lysing cells
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
DE102011079846B4 (de) 2011-07-26 2014-02-06 Merck Patent Gmbh Komplexverbindungen mit einem mehrzähnigen, asymmetrischen Liganden und ihre Verwendung im opto-elektronischen Bereich
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
WO2013049686A1 (en) 2011-09-30 2013-04-04 Tufts University Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders
JP6215212B2 (ja) * 2011-10-20 2017-10-18 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
JP6100274B2 (ja) 2011-11-11 2017-03-22 メルク パテント ゲーエムベーハー アリールアミンの調製方法
WO2013168103A1 (en) 2012-05-09 2013-11-14 Sasol Technology (Proprietary) Limited Oligomerisation of olefinic compounds with reduced polymer formation
JP6653573B2 (ja) 2012-05-22 2020-02-26 トラスティーズ・オブ・ダートマウス・カレッジ シクロアルカニル［ｂ］インドール、シクロアルカニル［ｂ］ベンゾフラン、シクロアルカニル［ｂ］ベンゾチオフェンを合成するための方法、化合物および使用の方法
DK2897948T3 (da) 2012-09-18 2016-12-05 Heptares Therapeutics Ltd Bicykliske aza-forbindelser som muskarin m1-receptoragonister
CA2885369A1 (en) 2012-09-28 2014-04-03 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
DE102012109685A1 (de) 2012-10-11 2014-04-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Umwandlung reaktiver Gruppen an Si-C-gebundenen Resten von Silanen unter gleichzeitiger Vergrößerung von deren räumlichem Abstand zueinander
WO2014065083A1 (ja) 2012-10-26 2014-05-01 コニカミノルタ株式会社 光学フィルム、円偏光板及び画像表示装置
JPWO2014068893A1 (ja) 2012-10-29 2016-09-08 コニカミノルタ株式会社 位相差フィルム、円偏光板、及び画像表示装置
JP5902641B2 (ja) 2013-03-27 2016-04-13 富士フイルム株式会社 光干渉顔料およびその製造方法
JP2014232188A (ja) 2013-05-29 2014-12-11 コニカミノルタ株式会社 セルロースアシレートフィルム、円偏光板及び画像表示装置
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
FR3009309B1 (fr) 2013-08-02 2016-10-07 Total Marketing Services Compositions lubrifiantes pour transmissions
JP2015030699A (ja) 2013-08-02 2015-02-16 マナック株式会社 アルカリ金属ハロゲン化物を用いたベンジルアミン類及びベンジルエーテル類の酸化的脱ベンジル化反応
WO2015024120A1 (en) 2013-08-19 2015-02-26 Queen's University At Kingston Carbene functionalized composite materials
KR102181235B1 (ko) 2013-08-30 2020-11-23 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR102167042B1 (ko) 2013-09-06 2020-10-19 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR102191991B1 (ko) 2013-09-06 2020-12-17 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR102191990B1 (ko) 2013-09-10 2020-12-17 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR20150091942A (ko) 2014-02-04 2015-08-12 삼성전자주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
WO2015126357A1 (en) 2014-02-18 2015-08-27 Renmatix, Inc. Method of reducing a fermentation and/or enzyme inhibitor in a saccharide-containing composition
US20150239918A1 (en) 2014-02-27 2015-08-27 Robert Lee Johnson Functionalized carbon matrix materials
JP6270180B2 (ja) 2014-03-07 2018-01-31 国立研究開発法人産業技術総合研究所 カルバミン酸エステルの製造方法
US9695168B2 (en) * 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
EP3250552B1 (en) * 2015-01-30 2019-03-27 Genentech, Inc. Therapeutic compounds and uses thereof
EP3286172B1 (en) * 2015-04-23 2019-06-12 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
RS64889B1 (sr) * 2016-10-26 2023-12-29 Constellation Pharmaceuticals Inc Inhibitori lsd1 i njihova medicinska upotreba
US20200069677A1 (en) * 2016-12-09 2020-03-05 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors

Also Published As

Publication number Publication date
CA3039793A1 (en) 2018-05-03
CN109863137A (zh) 2019-06-07
TW201821406A (zh) 2018-06-16
EP3532459A1 (en) 2019-09-04
PT3532459T (pt) 2023-11-10
FI3532459T3 (fi) 2023-10-23
US20200306223A1 (en) 2020-10-01
SI3532459T1 (sl) 2024-03-29
RS64889B1 (sr) 2023-12-29
JP2019537584A (ja) 2019-12-26
AU2017348100A1 (en) 2019-05-02
WO2018081343A1 (en) 2018-05-03
US20220079917A1 (en) 2022-03-17
US10517849B2 (en) 2019-12-31
JP7142633B2 (ja) 2022-09-27
US11013718B2 (en) 2021-05-25
CN109863137B (zh) 2022-12-16
EP3532459B1 (en) 2023-08-02
ES2961499T3 (es) 2024-03-12
US11547695B2 (en) 2023-01-10
TWI753037B (zh) 2022-01-21
LT3532459T (lt) 2023-11-10
US20190274998A1 (en) 2019-09-12
HRP20231369T1 (hr) 2024-02-16
HUE063848T2 (hu) 2024-02-28
AU2017348100B2 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3380101T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3452485T3 (da) Arginasehæmmere og deres terapeutiske anvendelser
DK3193611T3 (da) Mk2-inhibitorer og anvendelser deraf
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3256598T3 (da) Svampestammer og anvendelsesfremgangsmåder
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3268374T3 (da) Kv1.3-inhibitorer og deres medicinske anvendelse
DK3142659T3 (da) Hiv-1 proteasehæmmere og anvendelser deraf
DK3426243T3 (da) 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
DK3692009T3 (da) Biocementationsfremgangsmåde og system
DK3231793T3 (da) Dihydropyromidin-2-on-forbindelser og medicinske anvendelser deraf
DK3458650T3 (da) Fremgangsmåde til desinficering og vandhaneforbindelsesarrangement dertil
DK3240821T3 (da) Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3490988T3 (da) Ny forbindelse og fremgangsmåde